abstract: PURPOSE: The purposes of this study were to assess a) the effectiveness of Masai Barefoot Technology ( @entity8758 ) shoe in reducing knee @entity158 in @entity1 with @entity626 ( @entity571 ) and (b) changes in balance, ankle and knee ROM, and ankle strength compared with a high-end walking shoe for 12 wk. METHODS: The research design was a randomized controlled trial (123 subjects, knee @entity571 ). Subjects were randomized to a @entity8758 (N = 57) or a control shoe (N = 66). A Western Ontario and McMaster Universities (WOMAC) @entity571 index, BMI, balance, active ROM, and ankle torque were quantified at week 0, 3, 6, 9, and 12. Two-sample t-tests were done for between-group comparisons. RESULTS: There was no significant difference between groups in total @entity158 score. A significant reduction over the 12-wk period was found for both shoe conditions (-42/500 or 25.6% @entity8758 , -46.2 or 27.1% control). There was no significant group difference in @entity158 during walking (t = -1.09, P = 0.28). @entity158 during walking was significantly reduced by 5.2/100 mm in the @entity8758 and 9.7/100 mm in the control group. @entity158 showed a significant reduction for the @entity8758 -27.4/500 (-16.6%) and the control group -28.9/500 (-17.0%) between baseline and week 3. Between week 3 and 6, there was a significant reduction for the @entity8758 group only (-27.2/500 or -20.0%). There was a significant increase in the static balance between baseline and 12 wk in the @entity8758 group only, although the difference between groups was not significant. DISCUSSION: The results indicate that special shoe interventions can reduce @entity158 in subjects with moderate knee @entity571 .

title: Unstable shoe construction and reduction of XXXX in @entity571 @entity1 .

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain', 'Total pain']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: PURPOSE: We recently reported on the efficacy of intralesional rituximab for treating @entity706 in a pilot study. After treatment, a complete response was observed in two of five @entity1 , a partial response in one @entity1 , and lesion recurrence in two @entity1 . In this study, we evaluate the long-term follow-up of the five previously treated @entity1 as well as the response of two new @entity1 to an augmented dose of rituximab. METHODS: We followed up the five @entity1 who were treated with rituximab during the initial pilot study. Two additional @entity1 were also enrolled and treated with four intraorbital injections of 10 mg rituximab once a week for 1 month (total dose of 40 mg). Median follow-up period was 4 years for the first five @entity1 and 1 year for the last two @entity1 . RESULTS: Lymphoma did not relapse in the two @entity1 who originally responded immediately to treatment. Of the initial partial responders, one became disease-free after additional rituximab treatment, and one experienced a standardized uptake value reduction, as measured with positron emission tomography-CT. One @entity1 who experienced abdominal and pulmonary localization 7 months later showed no local recurrence. The two newly enrolled @entity1 had complete remission after the first cycle of treatment and no disease recurrence eight and 11 months later, respectively. CONCLUSIONS: This study suggests that intralesional administration of rituximab for treating localized ocular adnexal @entity2225 + @entity706 could be an effective front-line therapeutic option with negligible side effects and a good response rate and duration.

title: Long-term outcomes of XXXX treatment with intraorbital rituximab injections.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['primary ocular adnexal lymphoma', 'lymphomas']

answer: @entity706 :: (MESH:D008223,Disease) :: ['primary ocular adnexal lymphoma']


abstract: As a measure of cosmetic outcome, the compliance of normal and irradiated breasts has been quantified using a new method of Breast Compliance Evaluation (BCE). A total of 151 @entity1 were studied, of whom 100 were normal controls and 51 had previous breast irradiation as part of breast-conserving treatment. Compliance was taken as the difference between the anterior breast surface length from infra-mammary fold to the nipple when the @entity1 was in erect and supine positions. Irradiated cases were rated as having satisfactory outcome (good or excellent cosmetic result) or unsatisfactory (fair or poor cosmetic result). Mean compliance of normal cases was 1.8 cm. In the irradiated @entity1 with satisfactory cosmetic results, mean compliance was 1.45 compared with only 0.77 cm in those with unsatisfactory outcome. The difference between the compliance of both breasts was 0.1 cm for the controls, 0.3 cm in the satisfactory group and 2 cm in the unsatisfactory group. A difference in compliance greater than 1 cm was usually associated with an unsatisfactory cosmetic outcome. Factors determining cosmetic outcome included volume of excised lump and breast size. The cosmetic result was not affected by @entity5 site, clinical or pathological @entity5 size, or the total number of axillary nodes excised. This simple, painless, and easily reproducible measurement may be a useful objective indicator of cosmetic result after conservative treatment of early @entity0 .

title: Breast compliance: a new method for evaluation of cosmetic outcome after conservative treatment of early XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: Studies in animals and @entity1 report @entity935 agonists can improve neglect. Because @entity935 deficit reduces intention to act, it has been suspected the @entity935 agonist @entity2847 would improve deficient hemispatial intention. Thus, the effect of @entity2847 on line bisection was examined in a @entity1 with neglect and failure of the action-intention system. The 58-year-old @entity1 had left-sided neglect from a right cerebral @entity1188 . It was determined that neglect on a line bisection task was attributable to a motor-intentional bias by testing under congruous and incongruous video monitoring. Testing sessions were held before starting @entity2847 , on 20 mg/d, and after stopping @entity2847 . The @entity1 's ipsilesional bias increased on @entity2847 , and improved when @entity2847 was stopped. @entity2847 may worsen neglect if putamenal receptors are damaged. @entity935 agonists may activate the normal hemisphere, increasing an intentional bias. Clinicians using dopaminergic pharmacotherapy should assess @entity1 for this possible adverse effect.

title: Adverse effect of XXXX agonist therapy in a @entity1 with motor-intentional neglect.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'patient']

entities_list: @entity2847 :: ('MESH:D001971', 'Chemical') :: ['bromocriptine', 'Bromocriptine']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarction involving both cortical and subcortical (striatal) structures']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['Dopamine', 'dopamine']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['dopamine']


abstract: PURPOSE: The difficulties of fluid therapy in @entity1 with @entity326 are to maintain sufficient vascular volume while preventing @entity3126 formation. Thus, it is important to find a biomarker that can reliably predict @entity3126 formation after fluid loading. We evaluated the association of plasma protein levels with the increase in extravascular lung water index (/\EVLWI) after fluid loading. METHODS: This was an observational study in which we retrospectively reviewed medical records of septic @entity1 in whom hemodynamic variables were measured by transpulmonary thermodilution technique before and after fluid loading. Plasma protein levels were measured before fluid loading. @entity1 were divided into 2 groups according to the changes in EVLWI (/\EVLWI >=  10%) after fluid loading. Diagnostic performance of plasma proteins in predicting @entity3126 formation was assessed. RESULTS: A total of 62 @entity1 were included, and 27 of them showed a /\EVLWI 10% or higher after fluid loading. Plasma albumin and @entity69 were significantly lower in this group than in the group with /\EVLWI less than 10% (21.7    5.8 vs 25.3    5.0 g/L for albumin, P < .05; 107.9    50.1 vs 136.8    44.2 mg/dL for @entity69 , P < .05). Areas under the curve of albumin and @entity69 were 0.68 (cardiac index, 0.54-0.83) and 0.72 (cardiac index, 0.59-0.86), respectively. At a cutoff value of 87.9 mg/dL, @entity69 had a sensitivity of 0.91 in predicting /\EVLWI 10% or higher. CONCLUSIONS: Plasma @entity69 and albumin levels were associated with /\EVLWI 10% or higher after fluid loading. The high sensitivity of both biomarkers indicated that @entity1 with normal values were less likely to develop @entity3126 after fluid loading.

title: Prediction of @entity3126 by plasma protein levels in XXXX with sepsis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of @entity4053 by interrupting insulin delivery at a preset sensor @entity413 value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in @entity1 with @entity4053 . METHODS: We randomly assigned @entity1 with type 1 @entity6 and documented @entity4053 to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor @entity413 values. RESULTS: A total of 247 @entity1 were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 @entity1 ) or standard sensor-augmented insulin-pump therapy (control group, 126 @entity1 ). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980    1200 mg per deciliter [54.4    66.6 mmol per liter]   minutes vs. 1568    1995 mg per deciliter [87.0    110.7 mmol per liter]   minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5    1.0 vs. 2.2    1.3 per @entity1 -week, P<0.001). The percentages of nocturnal sensor @entity413 values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor @entity413 value was 92.6    40.7 mg per deciliter (5.1    2.3 mmol per liter). Four @entity1 (all in the control group) had a severe hypoglycemic event; no @entity1 had @entity6 . CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced @entity4053 , without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).

title: Threshold-based insulin-pump interruption for reduction of XXXX .

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic ketoacidosis', 'diabetes']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia', 'nocturnal hypoglycemia']

answer: @entity4053 :: (MESH:D007003,Disease) :: ['hypoglycemia']


abstract: A 27-year-old @entity1 was admitted to hospital because of severe @entity712 . Investigation revealed @entity384 with a left ventricular ejection fraction of 15-20%. During adolescence the @entity1 had been investigated for @entity851 and he also had progressive external @entity4610 . There had been no symptoms of @entity299 until 2 weeks before admittance. An endomyocardial biopsy showed @entity942 in cytochrome c oxidase (COX) in a mosaic pattern. A skeletal muscle biopsy showed @entity3055 with @entity7319 ragged-red fibers. Molecular genetic analysis revealed a heteroplasmic, 3.8-kb, mitochondrial DNA (mtDNA) deletion in heart and muscle. PCR-based quantification of the proportion of mtDNA with deletion showed 47% mutated mtDNA in the myocardial biopsy and 68% in muscle. In spite of treatment, the condition deteriorated and the @entity1 died 5 days after admittance. This case demonstrates that mtDNA deletions may occasionally be the cause of severe @entity384 , and that morphological and molecular genetic diagnosis may be obtained by endomyocardial biopsy.

title: XXXX associated with a mitochondrial DNA deletion.

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['growth retardation']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity3055 :: ('MESH:D017240', 'Disease') :: ['mitochondrial myopathy']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['dilated cardiomyopathy']

entities_list: @entity7319 :: ('MESH:D030401', 'Disease') :: ['COX-deficient']

entities_list: @entity4610 :: ('MESH:D009886', 'Disease') :: ['ophthalmoplegia']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac disease']

entities_list: @entity942 :: ('MESH:D003677', 'Disease') :: ['cardiomyocytes deficient']

answer: @entity384 :: (MESH:D002311,Disease) :: ['Fatal dilated cardiomyopathy']


abstract: OBJECTIVE: @entity551 ( @entity551 ) and mean arterial pressure (MAP) are essential evaluation elements in ill @entity1 , but there is wide variation among different sources defining systolic @entity551 in @entity1 , and there are no normal reference values for MAP. Our goal was to calculate the 5th percentile @entity551 and MAP values in @entity1 from recently updated data published by the task force working group of the National High Blood Pressure Education Program and compare these values with the lowest limit of acceptable @entity551 and MAP defined by different sources. DESIGN: Mathematical analysis of clinical database. METHODS: The 50th and 95th percentile @entity551 values from task force data were used to derive the 5th percentile value for @entity1 from 1 to 17 yrs of age stratified by height percentiles. MAP values were calculated using a standard mathematical formula. Calculated @entity551 values were compared with systolic @entity551 definitions from other sources. Linear regression analysis was applied to create simple formulas to estimate 5th percentile @entity551 and 5th and 50th percentile MAP for different age groups at the 50th height percentile. RESULTS: A 9-21% range in both @entity551 and MAP values was noted for different height percentiles in the same age groups. The 5th percentile @entity551 values used to define @entity551 by different sources are higher than our calculated values in @entity1 but are lower than our calculated values in adolescents. Clinical formulas for calculation of @entity551 and MAP (mm Hg) in normal @entity1 are as follows: @entity551 (5th percentile at 50th height percentile) = 2 x age in years + 65, MAP (5th percentile at 50th height percentile) = 1.5 x age in years + 40, and MAP (50th percentile at 50th height percentile) = 1.5 x age in years + 55. CONCLUSION: We developed new estimates for values of 5th percentile @entity551 and created a table of normal MAP values for reference. @entity551 is significantly affected by height, which has not been considered previously. Although the estimated lower limits of @entity551 are lower than currently used to define @entity551 , these values are derived from normal healthy @entity1 and are likely not appropriate for critically ill @entity1 . Our data suggest that the current values for @entity551 are not evidence-based and may need to be adjusted for @entity1 height and, most important, for clinical condition. Specifically, we suggest that the definition of @entity551 derived from normal @entity1 should not be used to define the @entity551 goal; a higher target @entity551 is likely appropriate in many critically ill and injured @entity1 . Further studies are needed to evaluate the appropriate threshold values of @entity551 for determining @entity551 .

title: Analysis of the evidence for the lower limit of systolic and mean arterial pressure in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['Systolic blood pressure', 'hypotension', 'SBP']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: @entity132 following right-hemisphere @entity64 is a common and disabling disorder, for which there is currently no effective pharmacological treatment. @entity935 agonists have been shown to play a role in selective attention and working memory, two core cognitive components of neglect. Here, we investigated whether the @entity935 agonist @entity26742 would have a beneficial effect on @entity132 in @entity64 @entity1 . A double-blind, randomized, placebo-controlled ABA design was used, in which each @entity1 was assessed for 20 testing sessions, in three phases: pretreatment (Phase A1), on transdermal @entity26742 for 7-11 days (Phase B) and post-treatment (Phase A2), with the exact duration of each phase randomized within limits. Outcome measures included performance on cancellation (visual search), line bisection, @entity227 , selective attention and sustained attention tasks, as well as measures of motor control. Sixteen right-hemisphere @entity64 @entity1 were recruited, all of whom completed the trial. Performance on the Mesulam shape cancellation task improved significantly while on @entity26742 , with the number of targets found on the left side increasing by 12.8% (P   =   0.012) on treatment and spatial bias reducing by 8.1% (P   =   0.016). This improvement in visual search was associated with an enhancement in selective attention but not on our measures of working memory or sustained attention. The positive effect of @entity26742 on visual search was not associated with the degree of preservation of prefrontal cortex and occurred even in @entity1 with significant prefrontal involvement. @entity26742 was not associated with any significant improvement in motor performance. This proof-of-concept study suggests a beneficial role of dopaminergic modulation on visual search and selective attention in @entity1 with @entity132 following @entity64 .

title: The effects of the XXXX agonist @entity26742 on @entity132 following @entity64 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual working memory']

entities_list: @entity26742 :: ('MESH:C047508', 'Chemical') :: ['rotigotine', 'Rotigotine']

entities_list: @entity132 :: ('MESH:D010468', 'Disease') :: ['Hemispatial neglect', 'hemispatial neglect']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine', 'Dopamine']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['dopamine']


abstract: A randomized, double-blind, parallel-group clinical study was conducted to compare the efficacy, tolerability, and safety of @entity19611 320 mg I/mL (Optiray, 320 Mallinckrodt Medical, Inc., St. Louis, MO) and @entity6111 300 mg I/mL (Omnipaque 300, Winthrop Pharmaceuticals, New York, NY). The study was conducted in 50 @entity1 undergoing peripheral arteriography and in ten @entity1 undergoing visceral arteriography. In the peripheral group, 92% of the radiographs acquired using Optiray were rated excellent or good. Eighty-eight percent of those acquired with Omnipaque were so rated. In the visceral study all radiographs in both groups were rated excellent or good. @entity1 tolerance was also impressive. We used a four-point rating scale (1 - none; 4 = severe) to score both heat and @entity158 sensations. For peripheral @entity1 the average heat score was 2.4 in the Optiray group versus 2.3 in the Omnipaque group. The average @entity158 scores were 1.1 in both groups. For visceral @entity1 , the average heat scores were 2.4 in both groups, while the @entity158 scores were 1.7 for the Optiray group versus 1.0 for the Omnipaque group. No clinically significant changes in vital signs were observed in any of the @entity1 . One clinically significant change in the electrocardiogram (ECG) tracing was noted after an Optiray injection, but it was not felt to be drug induced. There were five instances in which laboratory values rose from their normal baseline values, but all changes were minor. There was only one adverse reaction in the entire study. A short episode of coughing occurred in one @entity1 who received Omnipaque for a peripheral study; the coughing resolved spontaneously. Both Optiray and Omnipaque proved to be efficacious, well tolerated, and safe for intra-arterial use in peripheral and visceral vessels.

title: A double-blind comparative study of the safety, tolerability, and efficacy of @entity19611 and XXXX in peripheral and visceral arteriography.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

answer: @entity6111 :: (MESH:D007472,Chemical) :: ['iohexol']


abstract: Objective. This study identifies the prevalence of emotional and @entity146 and the associated factors in orphanage @entity1 . Methods. This cross-sectional study was conducted in three private orphanages in Cairo. Two hundred sixty-five @entity1 of ages ranging from 6 to 12 years living in three different orphanages care systems were included in the study. A sociodemographic information form and the @entity1 Behavior Checklist (CBCL) were used. @entity1 were clinically interviewed and @entity146 were identified. Diagnoses were done according to the manual for diagnosis and statistics of @entity146 fourth version (DSMIV). A written formal consent from the director of social solidarity was obtained before inclusion in the study. Results. The prevalence of behavioral disturbances was 64.53% among those in institutional care and the most prominent @entity146 were nocturnal enuresis (23.3%), @entity71 ( @entity71 ) (19.62%), @entity952 (17.36%). Age at first admission, causes of receiving institutional care, and moves 2 or more times between institutions were significantly associated with an increased risk of @entity146 . Conclusion. Our study showed that @entity1 living in institutions are prone to suffer from @entity146 . Stability of the caregiver acts as a protective variable.

title: Psychiatric Morbidity among a Sample of Orphanage XXXX in Cairo.

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'children', 'Children']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['ADHD', 'attention deficit hyperkinetic disorder']

entities_list: @entity952 :: ('MESH:D019958', 'Disease') :: ['oppositional defiant disorder']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral problems', 'psychiatric disorders', 'behavioral and emotional problems', 'mental disorder']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: The effects of @entity1092 ( @entity2052 ) and delta sleep-inducing peptide (DSIP) on metaphit-induced generalized, audiogenic @entity410 in adult @entity35 males were compared. The animals were i.p. injected with: (1) Saline; (2) metaphit (mp, 10 mg kg(-1)); 3. metaphit (10 mg kg(-1)) and 8 h later with DSIP (0.1, 0.2, 0.4 or 1.0 mg kg(-1)), 4. metaphit (10 mg kg(-1)) and 8 h later with @entity2052 (50, 75 or 100 mg kg(-1)); 5. DSIP alone (1.0 mg kg(-1)) and 6. @entity2052 , alone (100 mg kg(-1)). The @entity35 were exposed to sound stimulation at hourly intervals and the behavior and EEG were analyzed. The EEG signals in metaphit @entity35 appeared as a sleep-like pattern and spike-wave complexes with increased power spectra. @entity1092 and DSIP reduced the incidence of @entity410 and prolonged duration of latency in a dose-dependent manner. ED50 of @entity1092 in the 1st hour after administration was 63.19 mg kg(-1) and that of DSIP 3.19 mg kg(-1) four hours after injection. This suggests that @entity2052 , reached a peak of action immediately after the application, while DSIP had a prolonged action, mildly reducing, but not abolishing metaphit @entity410 . None of the applied @entity2052 and @entity23830 doses eliminated the metaphit-provoked EEG signs of @entity302 .

title: XXXX and delta-sleep peptide display high efficacy against metaphit-induced audiogenic @entity410 in @entity35 .

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproate', 'Valproate']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptiform activity']

answer: @entity1092 :: (MESH:D014635,Chemical) :: ['Valproate']


abstract: PURPOSE: @entity1 infected with @entity1082 ) with normal cytology to mild abnormalities currently have no treatment options other than watchful waiting or surgery if high-grade cervical @entity5 develop. A therapeutic vaccine would offer the possibility of preventing high-grade lesions in @entity1083 @entity1 . GTL001 is a therapeutic vaccine composed of recombinant @entity1799 and HPV18 E7 proteins fused to catalytically inactive @entity7320 CyaA. This study examined the tolerability and immunogenicity of GTL001 in @entity1 infected with @entity1799 or HPV18 with normal cytology. EXPERIMENTAL DESIGN: This was a phase I trial (EudraCT No. 2010-018629-21). In an open-label part, subjects received two intradermal vaccinations 6 weeks apart of 100 or 600  g GTL001 + topical 5% @entity553 cream at the injection site. In a double-blind part, subjects were randomized 2:1:1 to two vaccinations 6 weeks apart of 600  g GTL001 + @entity553 , 600  g GTL001 + placebo cream, or placebo + @entity553 . RESULTS: Forty-seven @entity1 were included. No dropouts, treatment-related serious adverse events, or dose-limiting @entity137 occurred. Local reactions were transient and mostly mild or moderate. @entity1799 /18 viral load decreased the most in the 600  g GTL001 + @entity553 group. In post hoc analyses, the 600  g GTL001 + @entity553 group had the highest rates of initial and sustained @entity1799 /18 clearance. @entity553 increased antigen-specific T-cell response rates but not rates of solicited reactions. All subjects seroconverted to CyaA. CONCLUSIONS: For @entity1 infected with @entity1799 or HPV18 with normal cervical cytology, GTL001 was immunogenic and had acceptable safety profile. Clin Cancer Res; 1-11.   2016 AACR.

title: GTL001, A Therapeutic Vaccine for XXXX Infected with @entity1799 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.

entities_list: @entity7320 :: ('520', 'Species') :: ['Bordetella pertussis']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['lesions or cancer']

entities_list: @entity1083 :: ('MESH:D030361', 'Disease') :: ['HPV-infected']

entities_list: @entity553 :: ('MESH:C056493', 'Chemical') :: ['imiquimod', 'Imiquimod']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

answer: @entity1 :: (9606,Species) :: ['Women']


abstract: OBJECTIVES: Following pediatric moderate-to-severe @entity131 (msTBI), few predictors have been identified that can reliably identify which individuals are at risk for long-term cognitive difficulties. This study sought to determine the relative contribution of detailed descriptors of @entity130 as well as demographic and psychosocial factors to long-term cognitive outcomes after pediatric msTBI. METHODS: @entity1 included 8- to 19-year-olds, 46 with msTBI and 53 uninjured @entity23 ( @entity23 ). Assessments were conducted in the post-acute and chronic stages of recovery. Medical record review provided details regarding acute @entity130 . Parents also completed a measure of premorbid functioning and @entity146 . The outcome of interest was four neurocognitive measures sensitive to msTBI combined to create an index of cognitive performance. RESULTS: Results indicated that none of the detailed descriptors of acute @entity130 predicted cognitive performance. Only the occurrence of injury, parental education, and premorbid academic competence predicted post-acute cognitive functioning. Long-term cognitive outcomes were best predicted by post-acute cognitive functioning. DISCUSSION: The findings suggest that premorbid factors influence cognitive outcomes nearly as much as the occurrence of a msTBI. Furthermore, of youth with msTBI who initially recover to a level of moderate disability or better, a brief cognitive battery administered within several months after injury can best predict which individuals will experience poor long-term cognitive outcomes and require additional services.

title: The UCLA study of Predictors of Cognitive Functioning Following Moderate/Severe Pediatric XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Participants']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['traumatic brain injury']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral problems']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['healthy controls', 'HC']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injury severity']

answer: @entity131 :: (MESH:D001930,Disease) :: ['Traumatic Brain Injury']


abstract: @entity130 @entity1 presenting with a Glasgow @entity772 Scale (GCS) score of 14-15 are considered to have mild @entity131 ( @entity131 ) with overall good neurologic outcomes. Current practice consists of initial stabilization, followed by a head CT, and neurosurgical consultation. Aside from serial neurologic examinations, @entity1 with a GCS of 15 rarely require neurosurgical intervention. In this study, we examined the added value of neurosurgical consultation in the care of @entity1 after @entity131 with a GCS of 15. We retrospectively reviewed the medical records of @entity1 presenting after @entity130 with an abnormal head CT and GCS of 15 between January 2004 and January 2005. @entity1 with a normal head CT and <48 hours hospital stay were excluded. Data included demographics, mechanisms of @entity130 Severity Score, the radiologists' dictated interpretations of the head CT, and neurosurgical interventions. Fifty-six @entity1 met the inclusion criteria. The mean age was 41+/-2.3 years, and the mean Injury Severity Scores was 10.2 +/-0.6. Mechanisms of injury included 64 per cent motor vehicle crash, 16 per cent motorcycle crash, 13 per cent fall, and 7 per cent all-terrain vehicle crash. The initial CT scans showed 43 per cent parenchymal contusions, 38 per cent @entity510 , 14 per cent @entity3439 , and 5 per cent @entity4282 . All @entity1 received a routine follow-up head CT, and 16 per cent showed changes (five improved and four were worse compared with initial CT scans). None of these @entity1 received a neurosurgical intervention, and two were transferred to a rehabilitation service. In this era of limited resources, @entity130 @entity1 who present with a GCS score of 15 after mild @entity131 can be safely managed without neurosurgical consultation, even in the presence of an abnormal head CT scan.

title: Utility of neurosurgical consultation for mild XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury']

entities_list: @entity3439 :: ('MESH:D006408', 'Disease') :: ['subdural hematomas']

entities_list: @entity4282 :: ('MESH:D046748', 'Disease') :: ['epidural hematomas']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injury, Injury', 'blunt trauma', 'Trauma', 'trauma']

answer: @entity131 :: (MESH:D001930,Disease) :: ['traumatic brain injury']


abstract: BACKGROUND: We evaluated the contribution of sentinel-node biopsy to outcomes in @entity1 with newly diagnosed @entity320 . METHODS: @entity1 with a primary @entity320 were randomly assigned to wide excision and postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred, or to wide excision and sentinel-node biopsy with immediate lymphadenectomy if nodal micrometastases were detected on biopsy. RESULTS: Among 1269 @entity1 with an intermediate-thickness primary @entity320 , the mean (+/-SE) estimated 5-year disease-free survival rate for the population was 78.3+/-1.6% in the biopsy group and 73.1+/-2.1% in the observation group (hazard ratio for recurrence[corrected], 0.74; 95% confidence interval [CI], 0.59 to 0.93; P=0.009). Five-year @entity320 -specific survival rates were similar in the two groups (87.1+/-1.3% and 86.6+/-1.6%, respectively). In the biopsy group, the presence of @entity3 in the sentinel node was the most important prognostic factor; the 5-year survival rate was 72.3+/-4.6% among @entity1 with @entity5 -positive sentinel nodes and 90.2+/-1.3% among those with @entity5 -negative sentinel nodes (hazard ratio for @entity204 , 2.48; 95% CI, 1.54 to 3.98; P<0.001). The incidence of sentinel-node micrometastases was 16.0% (122 of 764 @entity1 ), and the rate of nodal relapse in the observation group was 15.6% (78 of 500 @entity1 ). The corresponding mean number of @entity5 -involved nodes was 1.4 in the biopsy group and 3.3 in the observation group (P<0.001), indicating disease progression during observation. Among @entity1 with nodal @entity3 , the 5-year survival rate was higher among those who underwent immediate lymphadenectomy than among those in whom lymphadenectomy was delayed (72.3+/-4.6% vs. 52.4+/-5.9%; hazard ratio for @entity204 , 0.51; 95% CI, 0.32 to 0.81; P=0.004). CONCLUSIONS: The staging of intermediate-thickness (1.2 to 3.5 mm) primary @entity320 according to the results of sentinel-node biopsy provides important prognostic information and identifies @entity1 with nodal @entity3 whose survival can be prolonged by immediate lymphadenectomy. (ClinicalTrials.gov number, NCT00275496 [ClinicalTrials.gov].).

title: Sentinel-node biopsy or nodal observation in XXXX .

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'melanomas', 'cutaneous melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']


abstract: OBJECTIVE: To determine the efficacy of IV albumin in the prevention of severe @entity43 ( @entity43 ). DESIGN: Prospective study group with historical control. SETTING: University hospital-based IVF program. @entity1 (S): Between 1993 and 1995, 42 consecutive @entity1 undergoing IVF-ET or tubal ET who had serum E2 levels > or = 3,600 pg/mL (conversion factor to SI unit, 3.671) on the day of hCG administration and/or > or = 20 oocytes retrieved were considered at high risk for severe @entity43 and were selected as the control group. From December 1995 to October 1996, IV albumin was given to 30 consecutive @entity1 who fulfilled these criteria. INTERVENTION(S): The treatment group received IV albumin after oocyte retrieval. MAIN OUTCOME MEASURE: Occurrence of severe @entity43 . RESULT(S): None of the 16 @entity1 in the treatment group in nonconception cycles developed severe @entity43 , compared with 5 (21.7%) of 23 in the control group. In conception cycles, 4 (28.6%) of 14 @entity1 in the treatment group developed severe @entity43 , compared with 9 (47.4%) of 19 in the control group. All 4 @entity1 with @entity2099 in the treatment group developed severe @entity43 , compared with 3 (60%) of 5 in the control group. None of the 10 @entity1 with singleton pregnancies in the treatment group developed severe @entity43 , compared with 6 (42.9%) of 14 in the control group. CONCLUSION(S): Intravenous albumin prevents severe @entity43 in high-risk @entity1 who did not conceive or who carried singleton pregnancies, but not in the @entity1 with high-order pregnancies.

title: Intravenous albumin does not prevent the development of severe XXXX .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian hyperstimulation syndrome', 'OHSS']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENT']

entities_list: @entity2099 :: ('MESH:D011254', 'Disease') :: ['multiple pregnancies']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian hyperstimulation syndrome']


abstract: This report describes the perioperative management of @entity5642 occurring abruptly during a planned cystectomy for non-metastatic bladder @entity1377 . Peroperatively, profuse @entity548 and an acute decrease in blood pressure were effectively treated by blood transfusions and fresh frozen plasma. Haematological tests indicated the presence of @entity5642 . On the following three days, @entity810 , peripheral @entity5642 -related @entity882 and @entity5714 with schistocytes were suggestive of @entity9818 . Treatment by plasma exchange along with haemodialysis was commenced. An aetiological work-up remained negative. After 21 days of treatment, haemodialysis and plasma exchange were stopped. Urological outcome was favourable. The one-year follow-up did not show any residual @entity177 and laboratory parameters returned to normal. In the absence of evidence in favour of an infectious, drug-related or immunological aetiology, we postulated that this @entity9818 was caused by @entity5642 and that the @entity5 manipulation during the surgical procedure was the triggering factor.

title: Postoperative XXXX following radical cystectomy for bladder cancer.

entities_list: @entity9818 :: ('MESH:D057049', 'Disease') :: ['thrombotic microangiopathy']

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinoma']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity5642 :: ('MESH:D004211', 'Disease') :: ['disseminated intravascular coagulation']

entities_list: @entity5714 :: ('MESH:D000743', 'Disease') :: ['haemolytic anemia']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure']

answer: @entity9818 :: (MESH:D057049,Disease) :: ['thrombotic microangiopathy']


abstract: BACKGROUND: The influence of parental socio-economic status on childhood @entity5 treatment outcome in low-income countries has not been sufficiently investigated. Our study examined this influence and explored parental experiences during @entity5 treatment of their @entity1 in an Indonesian academic hospital. MATERIALS AND METHODS: Medical charts of 145 @entity1 diagnosed with @entity5 between 1999 and 2009 were reviewed retrospectively. From October 2011 until January 2012, 40 caretakers were interviewed using semi-structured questionnaires. RESULTS: Of all @entity1 , 48% abandoned treatment, 34% experienced @entity204 , 9% had progressive/ relapsed disease, and 9% overall event-free survival. Prosperous @entity1 had better treatment outcome than poor @entity1 (P<0.0001). Odds-ratio for treatment abandonment was 3.3 (95%CI: 1.4-8.1, p=0.006) for poor versus prosperous @entity1 . Parents often believed that their @entity1 's health was beyond doctor control and determined by luck, fate or God (55%). Causes of @entity5 were thought to be destiny (35%) or God's punishment (23%). Alternative treatment could (18%) or might (50%) cure @entity5 . Most parents (95%) would like more information about @entity5 and treatment. More contact with doctors was desired (98%). Income decreased during treatment (55%). Parents lost employment (48% fathers, 10% mothers), most of whom stated this loss was caused by their @entity1 's @entity5 (84% fathers, 100% mothers). Loss of income led to financial difficulties (63%) and debts (55%). CONCLUSIONS: Treatment abandonment was most important reason for treatment failure. Treatment outcome was determined by parental socio-economic status. @entity5 survival could improve if financial constraints and provision of information and guidance are better addressed.

title: Socio-economic status plays important roles in childhood XXXX treatment outcome in Indonesia.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Childhood cancer', 'cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'child']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: OBJECTIVES: @entity1289 ( @entity1289 ) inhibitors, which are frequently administered in @entity1 with @entity299 , have a known inhibitory effect on erythropoiesis. The aim of this study was to detect whether early @entity1289 inhibitor administration slows recovery from @entity417 following recent cardiac surgery. METHODS AND RESULTS: Forty male @entity1 with @entity417 (hemoglobin < 12 g/dL) an average of 9 days after cardiac surgery were randomized to receive @entity4688 ( @entity1289 inhibitor group) or not. All of the @entity1 received @entity20150 , 525 mg, in addition to standard therapy. @entity1 with @entity417 due to other causes were excluded. Blood samples were obtained at baseline, and after 8 days, 16 days, and 60 days. A 6-min walking test and echocardioscan were performed at baseline, and after 16 days and 60 days of treatment, and a chest radiograph was obtained at baseline and after 60 days. The @entity1289 inhibitor group showed a statistically significant lower increase in hemoglobin and RBC values. The peak between-group differences of 1 g/dL of hemoglobin (p = 0.012) and 444 RBCs per milliliter (p = 0.017) were observed on day 16. CONCLUSIONS: Early enalapril maleate administration in anemic @entity1 after heart surgery significantly inhibits erythropoiesis. This unfavorable effect on @entity417 should be considered when prescribing @entity1289 inhibitors for such @entity1 .

title: XXXX inhibitors slow recovery from @entity417 following cardiac surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity4688 :: ('MESH:D004656', 'Chemical') :: ['enalapril']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['ACE', 'Angiotensin-converting enzyme']

entities_list: @entity20150 :: ('MESH:C020748', 'Chemical') :: ['ferrous sulfate']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

answer: @entity1289 :: (1636,Gene) :: ['Angiotensin-converting enzyme']


abstract: OBJECTIVES: Endothelial progenitor cells (EPCs) might play important roles in vascular homeostasis. This study evaluated the influence of prematurity, @entity1468 ( @entity1468 ) and @entity1592 ( @entity1592 ) on the EPC population in @entity1 umbilical cord blood (CB). METHODS: CB was obtained from 19 preterm and 27 term deliveries. Mononuclear cells were isolated by gradient centrifugation and subjected to flow cytometry to obtain percentages of @entity1195 (d) @entity2280 +, @entity1195 (d) @entity5439 +, CD 45(d) @entity2280 + @entity5439 +, and @entity1195 (d) @entity2280 + @entity5439 + @entity319 + cells. Clinical data were obtained using chart review. RESULTS: Percentages of EPCs were comparable between preterm and term cord blood. @entity1195 (d) @entity2280 + @entity5439 + cells were significantly decreased in CB samples obtained from @entity1 with @entity1468 (n = 14) [0.01, (0.00-2.6), [median, (range)], as compared to those without @entity1468 (n = 32) [1.74 (0.00-3.1)] (p = 0.005). @entity1195 (d) @entity5439 + @entity2280 - cells were significantly increased in presence of @entity1468 [0.43, (0.06-1.38)], (p = 0.002). @entity1195 (d) @entity2280 + @entity5439 + cells were significantly decreased in presence of @entity1592 , with no change in @entity1195 (d) @entity5439 + @entity2280 - cells. Differences in EPC types associated with @entity1468 and @entity1592 were present only in term CB. CONCLUSIONS: Exposure to @entity1468 and @entity1592 is associated with significant changes in EPC population. Future studies are needed to explore the clinical impact of observed changes.

title: Effect of XXXX and @entity1592 on endothelial progenitor cells in @entity1 umbilical cord blood.

entities_list: @entity1592 :: ('MESH:D005317', 'Disease') :: ['IUGR', 'intrauterine growth restriction']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia', 'PE']

answer: @entity1468 :: (MESH:D011225,Disease) :: ['preeclampsia']


abstract: @entity1086 shows an unusual geographic and demographic distribution. It is relatively uncommon in Europe, but more frequent in Israel, Chile, Bolivia and in Southwestern Native Americans in the United States. @entity2679 , @entity2941 , high body mass index, female gender, age, @entity1239 and industrial exposure to carcinogens are associated risk factors. The frequency of @entity1086 in all operations of the biliary tract is about 1-3%, reflecting the commonest biliary tract @entity5 . Preoperative imaging, including ultrasound and computed tomography (CT), may reveal signs indicative of the presence of @entity5 . However, most @entity1 are not diagnosed prior to surgical intervention. Survival depends on the ability to achieve a curative resection, including hepatectomy and lymph node dissection in @entity1 with local extended @entity5 according to the stage of the disease. Overall, the curative resection rates for @entity1086 range from 10% to 30%. Regional and para-aortic lymphadenectomy provides no survival benefit for @entity1 with @entity2333 , which has a negative influence on prognosis equivalent to that of distant @entity3 . A survival benefit is seen only in selected @entity1 with @entity3 limited to the regional nodes. Taking a sample biopsy of the para-aortic nodes before starting surgery is recommended because these nodes are involved more frequently than expected. For those @entity1 with unresectable @entity5 , palliative surgical, endoscopic or radiological bypass procedures can improve quality of life. Other approaches to the management of advanced @entity5 include systemic chemotherapy or combined chemo-radiotherapy and need further evaluation. Early-stage @entity5 are often discovered as an incidental finding during (laparoscopic) cholecystectomy or on histological examination of the gallbladder, mostly necessitating relaparotomy and extensive resection. In the following, management of @entity1 with @entity1086 at different stages and situations is discussed.

title: XXXX and surgical treatment.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2941 :: ('MESH:D015529', 'Disease') :: ['choledochal cysts']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumours', 'malignancy', 'tumour']

entities_list: @entity1239 :: ('MESH:D009538', 'Chemical') :: ['nicotine']

entities_list: @entity2679 :: ('MESH:D002764', 'Disease') :: ['Chronic cholecystitis']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity1086 :: ('MESH:D005706', 'Disease') :: ['Gallbladder carcinoma', 'gallbladder cancer', 'gallbladder carcinoma']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['para-aortic disease']

answer: @entity1086 :: (MESH:D005706,Disease) :: ['Gallbladder carcinoma']


abstract: UNASSIGNED: @entity2783 is a @entity66 , which is characterized by the extracellular deposition of insoluble abnormal fibrils. Histological and subsequent immunohistochemical examinations are necessary for the determination of the diagnosis and the classification of the amyloid type. The most common systemic variant is immunoglobulin-derived light chain ( @entity1582 ) @entity2783 . However, local or organ-limited @entity1582 can occur. Isolated @entity2783 is a rare condition and frequently an incidental finding at chest scans or during autopsy. Generally, it is associated with a benign prognosis. Here, we present two fatal cases, in which the cause of @entity204 was @entity2063 due to severe @entity1503 . During autopsy, several nodules were found in the lungs. Based on histological and immunohistochemical analysis, the diagnosis of an isolated nodular pulmonary @entity1582 lambda light chain was made. Amyloid was also present in pulmonary blood vessels, which lead to @entity548 .

title: Nodular XXXX with @entity1503 .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['multisystem disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['fragility and finally fatal hemorrhage']

entities_list: @entity2783 :: ('MESH:D000686', 'Disease') :: ['Amyloidosis', 'pulmonary amyloidosis', 'amyloidosis']

entities_list: @entity2063 :: ('MESH:C537571', 'Disease') :: ['asphyxiation']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['AL amyloidosis', 'AL']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['blood aspiration']

answer: @entity2783 :: (MESH:D000686,Disease) :: ['pulmonary amyloidosis']


abstract: Chemokines play an important role in @entity5 @entity3 by modulating the directional cell movement and migration of @entity5 cells. The most commonly overexpressed @entity436 in @entity1 @entity5 is @entity436 . Once activated by its ligand @entity1570 (stromal cell-derived factor-1 ligand/ @entity1570 ), @entity436 stimulates several key migratory, proliferative and survival signaling cellular pathways. @entity436 is expressed in @entity151 ( @entity151 ) cells and other @entity5 . To further characterize the role of chemokines in @entity5 @entity3 , we analyzed the tissue expression of @entity436 and @entity1570 in the surgical specimen of a @entity1 with this phenomenon. We performed immunohistochemical analysis for the expression of @entity436 and @entity1570 in metastatic @entity5 tissue of a 69-year-old Caucasian male with extensive @entity151 metastatic to a @entity8880 . The @entity1637 tissue harboring @entity151 showed @entity1570 expression, but not @entity436 . A high expression of the two molecules was found in a normal renal parenchymal control. Our results suggest that @entity436 and @entity1570 plays a role in this condition, but their expression may be affected by the microenvironment of the harboring @entity5 . Further characterization of these phenomena is needed to shed light on the biological mechanisms of @entity5 @entity3 .

title: Chemokine expression in XXXX @entity3 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient']

entities_list: @entity8880 :: ('MESH:C537750', 'Disease') :: ['renal oncocytoma']

entities_list: @entity1637 :: ('MESH:D018249', 'Disease') :: ['oncocytoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumor-to-tumor', 'malignancy', 'tumors']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity151 :: ('MESH:D055752', 'Disease') :: ['small-cell lung carcinoma', 'SCLC']

entities_list: @entity436 :: ('7852', 'Gene') :: ['CXCR4', 'chemokine receptor']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor-to-tumor']


abstract: Four experiments were conducted to determine the effect of feeding dried pine needles (Pinus ponderosa; @entity6841 ) on the abortion rate of ruminants. In Exp. 1, @entity291 were fed 5.4 kg of @entity6841 daily for 21 d starting at 116, 167, 215, or 254 d of pregnancy. The @entity6841 did not cause abortions when started at 116 d; thereafter, the percentage of @entity291 that aborted increased linearly, and the interval to abortion decreased linearly (both P < .01); all @entity291 fed @entity6841 beginning at 254 d aborted. In Exp. 2, @entity291 were fed .7, 1.4, or 2.7 kg of @entity6841 for 21 d or 2.7 kg for 1 or 3 @entity742 and @entity1237 were fed .8 and .5 kg of @entity6841 , respectively, starting at 121 d of pregnancy. The @entity6841 induced some abortions in @entity291 when fed for 1 (11%) or 3 (30%) d, but the abortion rate was greater (P < .01) when the @entity6841 were fed for longer periods of time (80, 90, and 100% aborted in 19, 17, and 10 d for .7-, 1.4-, and 2.7-kg doses, respectively). No @entity1237 or @entity742 aborted in response to @entity6841 feeding. Pregnancy rates during the next breeding season for @entity291 that aborted in response to the @entity6841 were slightly higher than rates for control @entity291 (94 vs 87%). In Exp. 3, buffalo ( @entity11055 ) and @entity291 were fed 2.25 kg of @entity6841 from the same collection. Abortions were induced in all buffalo and @entity291 that were fed @entity6841 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Effects of feeding ponderosa pine needles during pregnancy: comparative studies with bison, XXXX , @entity1237 , and @entity742 .

answer: @entity291 :: (9913,Species) :: ['cattle']


abstract: A case of @entity2894 causing @entity548 with extension into the third ventricle is reported. The @entity1 was a 73-year-old, @entity28 female admitted with @entity391 and @entity1662 . Neurological examination revealed that she was stuporous, with marked neck stiffness and a dilated left pupil. A plain skull X-ray showed sellar enlargement and destruction of the dorsum sellae. Computed tomography demonstrated a high-density area in the third and lateral ventricles and a round, high-density mass in the suprasellar cistern. The @entity1 died the next day. Autopsy revealed a large @entity5 in the sellar and suprasellar areas. The @entity5 and the @entity1410 within it compressed the floor of the third ventricle and passed through the lamina terminalis and the hypothalamic region. Histological examination disclosed a @entity17730 . The @entity548 appeared to be the result of @entity63 and @entity39 within the @entity977 caused by its acute expansion. The extension of the @entity1410 into the third ventricle was attributable to the large size of the @entity5 and its close adhesion to the floor of third ventricle.

title: [ XXXX extending into the third ventricle. Case report].

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['pituitary hemorrhage']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['sudden onset of vomiting']

entities_list: @entity2894 :: ('MESH:D010899', 'Disease') :: ['pituitary apoplexy']

entities_list: @entity17730 :: ('MESH:D000237', 'Disease') :: ['basophilic adenoma']

entities_list: @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenoma']

entities_list: @entity1662 :: ('MESH:D003244', 'Disease') :: ['impaired consciousness']

answer: @entity548 :: (MESH:D006470,Disease) :: ['Pituitary hemorrhage']


abstract: INTRODUCTION: @entity65 remains the most common cause of @entity204 in the United States and most other Western nations. Among these deaths, sudden, out-of-hospital @entity1167 claims approximately 1000 lives each day in the United States alone. Most of these cardiac arrests are due to @entity2224 . Though highly reversible with the rapid application of a defibrillator, @entity2224 is otherwise fatal within minutes, even when cardiopulmonary resuscitation is provided immediately. The overall survival rate in the United States is estimated to be less than 5 percent. Recent developments in @entity4610 technology have provided a means of increasing the rate of prompt defibrillation after out-of-hospital @entity1167 . After minimal training, nonmedical personnel (e.g., flight attendants and casino workers) are also able to use defibrillators in the workplace, with lifesaving effects. Nonetheless, such programs have involved designated personnel whose job description includes assisting @entity1 who have had @entity1164 . Data are still lacking on the success of programs in which automated external defibrillators have been installed in public places to be used by @entity1 who have no specific training or duty to act. MATERIALS AND METHODS: All @entity1 who had an out-of-hospital @entity1167 between January 2003 and December 2004 and who received @entity8658 for @entity2224 were included. We conducted a 24 months retrospective population-based analysis of the outcome in our population. RESULTS: Over a 24 month period, 446 @entity1 had non-traumatic @entity1167 , and in all of them it was observed to be @entity2224 . In a very few cases, the defibrillator operators were good Samaritans, acting voluntarily. Eighty-nine @entity1 (about 19%) with @entity2224 were successfully resuscitated, including eighteen who regained consciousness before hospital admission. CONCLUSION: Automated external defibrillators deployed in readily accessible, well-marked areas, are really very effective in assisting @entity1 with @entity1167 . However, it's quite true that, in the cases of survivors, most of our users had good prior training in the use of these devices.

title: Early outcomes of out-of-hospital @entity1167 after XXXX : a 24 months retrospective analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people', 'persons']

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac arrest']

entities_list: @entity8658 :: ('MESH:C580055', 'Disease') :: ['early defibrillation']

entities_list: @entity4610 :: ('MESH:D009886', 'Disease') :: ['automated-external-defibrillator']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular disease']

answer: @entity8658 :: (MESH:C580055,Disease) :: ['early defibrillation']


abstract: PURPOSE: The unusual side effect of @entity3327 associated with the antidepressant @entity3346 has led researchers to evaluate its use for the treatment of @entity323 . Previous studies have shown nearly 70% efficacy in @entity1 . Unfortunately, these studies have been anecdotal, retrospective or of combination therapy with @entity3160 . A placebo controlled, fixed dose, double-blind crossover study was performed to evaluate the safety and efficacy of oral @entity3346 for the treatment of @entity323 . MATERIALS AND METHODS: A total of 51 @entity1 with at least 3 months of complete @entity323 were randomized in a double-blind fashion to receive 50 mg. @entity3346 or placebo at bedtime. Evaluation consisted of a history, physical examination and laboratory studies, including hormonal evaluation, nocturnal penile tumescence evaluation, penile Doppler ultrasound and the Index of Sexual Satisfaction. @entity1 were followed at monthly intervals with an in clinic interview. After a 3-month treatment interval @entity1 were reevaluated with index scores and crossed over after a 3-week washout period. Study end points included @entity1 diary evaluations and index scores at the beginning of the study interval and the end of the first treatment period. RESULTS: Of the 51 @entity1 who enrolled in the study 48 completed both phases. Mean @entity1 age was 65 years (range 31 to 80). After the first 3-month treatment interval 19% of @entity1 receiving @entity3346 had improved erections compared to 24% receiving placebo (p < 0.50). Of the @entity3346 group 35% had improvement in sex drive compared to 20% of the placebo group (p < 0.36). Mean Index of Sexual Satisfaction scores changed after treatment from 31.7 to 27.5 for the @entity3346 group (p < 0.50) and from 28.5 to 30.8 for the placebo group (p < 0.49). Side effects included drowsiness in 31% of the @entity1 , @entity2133 in 1% and fatigue in 19%. CONCLUSIONS: @entity3346 is no more effective than placebo in improving erections and sexual function in @entity1 with severe physiological @entity323 .

title: Oral @entity3346 is not effective therapy for XXXX : a double-blind, placebo controlled trial.

entities_list: @entity3346 :: ('MESH:D014196', 'Chemical') :: ['Trazodone', 'trazodone']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction']

entities_list: @entity3160 :: ('MESH:D015016', 'Chemical') :: ['yohimbine']

answer: @entity323 :: (MESH:D007172,Disease) :: ['erectile dysfunction']


abstract: The lack of classical @entity1 histocompatibility leukocyte antigen (HLA) molecules in @entity1 placenta prevents the recognition and lysis by maternal T lymphocytes but poses the problem of susceptibility to natural killer (NK) cell-mediated lysis. The nonclassical HLA class I molecule @entity6393 may mediate protection from NK cells. NK cells are known to express a number of HLA class I-specific inhibitory receptors. These include members of the immunoglobulin (Ig) superfamily ( @entity28383 , @entity19176 , @entity30026 ), characterized by a defined allele specificity, and @entity9706 / @entity9707 with a broad specificity for different HLA class I molecules. We analyzed a series of NK cell clones derived from normal peripheral blood expressing different @entity21319 ( @entity21319 ). Clones were analyzed for their cytolytic activity against the HLA class I-negative 221 cell line either untransfected or transfected with @entity6393 (221/G) or other informative alleles, as control. All clones expressing @entity9706 / @entity9707 [as identified by the Z199 monoclonal antibody (mAb)] displayed a markedly reduced cytolytic activity against 221/G. Moreover, mAb directed to the @entity9706 / @entity9707 complex completely restored target cell lysis. Among @entity9707 -negative NK clones, different functional patterns could be detected. Clones expressing inhibitory receptors belonging to the Ig superfamily lysed 221/G target cells with equal or higher efficiency than untransfected 221 cells. These data indicated that @entity28383 , @entity19176 and @entity30026 do not function as @entity6393 -specific inhibitory @entity21319 , and that @entity6393 -specific activating @entity21319 also exist. Further analysis indicated that in these clones (characterized by the @entity9706 +/ @entity9707 - phenotype) mAb specific for @entity9706 , but not for the other @entity21319 , reversed the activating effect. Infrequent clones were also isolated that, in spite of the lack of @entity9706 / @entity9707 , displayed @entity6393 specificity, thus suggesting the existence of a different, still unknown @entity21319 .

title: XXXX recognition by @entity1 natural killer cells. Involvement of @entity9706 both as inhibitory and as activating receptor complex.

answer: @entity6393 :: (3135,Gene) :: ['HLA-G']


abstract: Non-missile penetrating @entity3510 are rare. Screw @entity130 , more especially to the cervical spine, represents an even rarer subset. To our knowledge, this is the first reported case from West Africa of cervical @entity1566 from a screw driver. A middle-aged @entity1 was stabbed from the back with a screw driver. He presented with right-sided C4 @entity10302 with the impaling object in situ. Cervical spine x-rays showed the screw driver to have gone into the spine between the spinous processes of C4 and C5, traversing the spinal canal and lodged in the anterior part of the C4/5 intervertebral disc space. C4 and C5 laminectomies were performed and the screw driver removed under vision. The object was found to have traversed the right side of the cervical spinal cord. The dural tear was repaired. He had some neurologic improvement initially, but later declined. He died from severe @entity358 2 weeks postinjury. Screw driver represents an unusual cause of non-missile penetrating cervical @entity3510 . Its neurological effects and complications of the @entity1566 lead to significant morbidity and mortality.

title: Screw driver: an unusual cause of cervical XXXX .

entities_list: @entity3510 :: ('MESH:D013124', 'Disease') :: ['spinal injury', 'spinal injuries']

entities_list: @entity10302 :: ('MESH:D018437', 'Disease') :: ['Brown-Sequard syndrome']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary complications']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'cord injury']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['driver injury']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: BACKGROUND: @entity14 surgery carries a high risk of @entity1211 ( @entity1211 ) but the optimal duration of thromboprophylaxis is unknown. The cost-effectiveness of extended prophylaxis is not known in Australasia. The aims of this study were to determine the 30-day incidence of @entity1211 in @entity1 undergoing @entity14 surgery, to audit compliance with thromboprophylaxis protocols and to estimate the cost of treating all @entity1 for 28 days with @entity2120 . METHODS: @entity1 undergoing elective @entity14 surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database. Case note review was conducted for @entity1 demographics, @entity1211 risk factors, types of thromboprophylaxis used, complications, readmission rate and @entity1211 rate. Documented compliance with unit @entity1211 protocols was calculated. The cost of treating all @entity1 with enoxaparin as prophylaxis for 28 days was then estimated. RESULTS: A total of 254 @entity1 were identified. The in-hospital @entity1211 rate was 0.79% (2 out of 254). The post-discharge @entity1211 rate was 0.39% (1 out of 254). Compliance with thromboprophylaxis protocols was excellent. Pharmacological thromboprophylaxis was used in 97% of @entity1 , graduated compression stockings in 84% and pneumatic compression devices in 53%. The estimated cost of extended prophylaxis for all 254 @entity1 was  32,308.80. CONCLUSIONS: We have demonstrated excellent compliance with in-hospital thromboprophylaxis. Hence, we have low @entity1211 rates in-particular, post-discharge @entity1211 . The infrequency of post-discharge @entity1211 means that the cost-effectiveness of extended prophylaxis might be questioned.

title: Is extended thromboprophylaxis necessary in elective XXXX surgery?

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism']

entities_list: @entity2120 :: ('MESH:D017984', 'Chemical') :: ['enoxaparin']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: Genetic @entity9595 is characterised by an inappropriately high rate of @entity68 absorption by the small intestine. The disease is transmitted as an @entity74 . The gene frequency in the Caucasian population is approximately 1 in 20 and the disease frequency is 1 in 400. Excessive @entity68 deposition occurs in the liver, pancreas, heart, @entity2720 and hepatic @entity68 concentrations above approximately 400 mumol/g dry weight are always associated with @entity82 and usually with @entity82 and progressive @entity1578 . Accurate diagnosis depends upon the demonstration of elevated hepatic @entity68 stores. An hepatic @entity68 index [hepatic @entity68 concentration (in mumol/g dry weight) divided by @entity1 age] of greater than 2.0 distinguishes homozygous subjects from the other conditions in which slight increases in hepatic @entity68 concentration may occur, e.g. in a subject heterozygous for @entity9595 or @entity5881 . If @entity82 is present, @entity1 are at a high risk of developing @entity157 . Therefore, they should undergo regular abdominal ultrasound and @entity160 estimation. In the absence of @entity82 , phlebotomy restores life expectancy to normal. Venesection should be continued until all excess @entity68 stores are removed as judged by failure of a rise in haemoglobin concentration on cessation of phlebotomy. Screening of first degree relatives should commence from a young age (e.g. 10 years). If serum ferritin or @entity69 saturation are abnormal, liver biopsy should be undertaken. HLA typing of the family allows for the identification of those siblings who are most likely to develop the disease. Secondary @entity68 overload is often multifactorial in origin. @entity68 chelation therapy with subcutaneous @entity5532 ( @entity5532 ) should only commence after careful consideration of the potential benefits in each individual @entity1 .

title: Current concepts in rational therapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis', 'cirrhosis']

entities_list: @entity5881 :: ('MESH:D008108', 'Disease') :: ['alcoholic liver disease']

entities_list: @entity5532 :: ('MESH:D003676', 'Chemical') :: ['deferoxamine', 'desferrioxamine']

entities_list: @entity1578 :: ('MESH:D017093', 'Disease') :: ['liver failure']

entities_list: @entity160 :: ('174', 'Gene') :: ['alpha-fetoprotein']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['autosomal recessive condition']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['pituitary and joints']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma']

entities_list: @entity9595 :: ('MESH:D006432', 'Disease') :: ['haemochromatosis']

answer: @entity9595 :: (MESH:D006432,Disease) :: ['haemochromatosis']


abstract: The 18th and early 20th centuries witnessed the disintegration of a unified approach to understanding the @entity1 condition. Political economy, the broad study of @entity1 society, fragmented into an array of university-based disciplines, each reductionistically focused on its narrow arena of specialized research. Medicine, which had been concerned with health in social and historic contexts, narrowed its focus to the microscopic level and to encapsulated understandings of the immediate effects of pathogens and of the structures of disintegrated organ systems. Similarly, anthropology, which continued to wave a banner of holism, retreated for much of the 20th century into fine-grained cultural studies of seemingly isolated @entity1 communities on the one hand, and highly specialized biological and biobehavioral analyses of only tangential concern to cultural concerns on the other. Consequently, it has appeared at times as if anthropology would fragment into two or more disciplines and the opportunity for an integrated understanding of the @entity1 condition would be lost in the process. As we approach ever closer to the 21st century, however, the felt need for interdisciplinary and intradisciplinary reintegration has grown stronger. This trend is manifest increasingly in the field of @entity167 , @entity286 , and drug studies, and suggests one of the places anthropology may be going in the future. In this light, this paper examines the use of a critical biocultural model employed in the anthropological assessment of the Hartford Syringe Exchange Program. This model integrates the political economy of risk behavior, the ethnographic examination of insider understandings, meaning systems and behaviors, and the biological analysis of health-related issues. Methodologically, the assessment combined methods and concepts from all of the major subfields of anthropology.

title: Toward a bio-cultural and political economic integration of XXXX , @entity286 and drug studies in the coming century.

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

answer: @entity167 :: (CHEBI:16236,Chemical) :: ['alcohol']


abstract: OBJECTIVE: To study the relationship between gray matter @entity194 and @entity527 in @entity195 ( @entity195 ). METHODS: Volumetric magnetic resonance (MR) and @entity11703 PET were acquired from 23 @entity1 with @entity195 and 17 healthy older @entity1 . Standardized @entity11703 uptake values were coregistered to MR scans in a standard space. Decreased density of and increased @entity11703 uptake in the gray matter of @entity1 with @entity195 vs controls were assessed with both voxel-based (p < 0.05 corrected) and region-of-interest (ROI) analyses. The relationship between decreased density of and increased @entity11703 uptake in the gray matter was investigated with voxel-based Pearson r maps (thresholded at p < 0.05) and ROI linear regression plots. RESULTS: Atrophy mapped to the hippocampus and increased @entity11703 uptake to large frontal, parietal, and posterior cingulate cortical areas. ROI analysis showed the largest effect size for @entity194 in the hippocampus (2.01) and amygdala (1.27) and the highest effect size for @entity11703 uptake in frontal (2.66), posterior cingulate/retrosplenial (2.43), insular (2.41), and temporal (2.23) regions. In the hippocampus, @entity11703 uptake was significantly increased, but effect size was milder (1.72). Significant correlations between @entity194 and increased @entity11703 uptake were found in the hippocampal (r = -0.54) and amygdalar ROIs (r = -0.40) but not in the frontal, temporal, posterior cingulate/retrosplenial, insular, and caudate ROIs (r between 0.04 and 0.25). CONCLUSION: The medial temporal lobe might be highly susceptible to @entity137 , whereas neocortical areas might be more resilient.

title: In vivo mapping of @entity137 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['amyloid toxicity']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['amyloid deposition']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', 'Alzheimer disease']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer disease']


abstract: OBJECT: The purpose of this study was to evaluate the long-term safety and effectiveness of the ProDisc-L @entity348 ( @entity348 ) as part of an FDA-mandated postmarket approval study. This report summarizes the clinical findings after 5 years of follow-up. METHODS: Two hundred thirty-six @entity1 were treated and followed up for 5 years; 161 TDRs and 75 fusions had been performed in these @entity1 . The primary outcome was a 10-component success end point. Secondary outcome measures included @entity16 , secondary surgery, Oswestry Disability Index (ODI), 36-Item Short Form Health Survey (SF-36), visual analog scale (VAS) assessing @entity158 and satisfaction, radiographic data, narcotic use, activity, and recreation status. @entity1 were monitored through their 5-year postoperative visits under the FDA postmarket surveillance provisions in the original investigational device exemption approval. RESULTS: The overall follow-up rate at 5 years was 81.8%. Study success demonstrated that @entity348 was noninferior to fusion with a 12.5% margin (p = 0.0099). Both @entity348 and fusion treatment groups maintained significant improvement on the ODI at 5 years compared with baseline (p < 0.0001). Secondary surgeries at the index level were performed in 12% of fusion @entity1 and 8% of @entity348 @entity1 . Radiographically, none of the TDRs developed spontaneous fusion. The segmental range of motion following @entity348 remained within normal range, although it decreased by approximately 0.5   in years 3 to 5. The @entity227 scores decreased from preoperative values by 48% in both treatment groups at 5 years. @entity1 satisfaction remained high in both groups (77%), while the percentage of @entity1 indicating that they would have the surgery again was higher in @entity348 @entity1 (82.5%) than in fusion @entity1 (68.0%). CONCLUSIONS: @entity1 in both groups maintained significant improvement during the 5-year follow-up. The @entity348 group had significantly better improvement on some scales. Although @entity348 @entity1 avoid the stiffness of fusion and are more satisfied than fusion @entity1 , both fusion and @entity348 are reasonable surgical options in this specific @entity1 population.

title: Five-year results of the prospective, randomized, multicenter, Food and Drug Administration investigational device exemption study of the ProDisc-L XXXX versus circumferential arthrodesis for the treatment of single-level degenerative disc disease.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Patient']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological status']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['total disc replacement', 'TDR']

answer: @entity348 :: (MESH:C535338,Disease) :: ['total disc replacement']


abstract: BACKGROUND: Ischemic penumbra in @entity64 ( @entity64 ) can be evaluated using arterial @entity7959 -labeled (ASL) perfusion magnetic resonance imaging (MRI). We used three-dimensional ASL-MRI to examine @entity1 with @entity64 and the clinical utility of the method within 24 hours of @entity64 onset. SUBJECTS AND METHODS: The 55 male and 48 female @entity1 (mean age, 79.0 years) underwent diffusion-weighted imaging (DWI), fluid-attenuated inversion recovery imaging, magnetic resonance angiography, and pulsed continuous ASL perfusion imaging to determine @entity64 subtype, hypoperfused ASL area, and @entity51 severity (National Institutes of Health @entity64 Scale). Arterial transit artifacts, indicative of occlusive regions or collateral flow, and other @entity64 indices were compared. RESULTS: ASL hypoperfusion was detected in 3 of 9 @entity1 with @entity63 ( @entity63 ), 2 of 27 @entity1 with @entity1188 ( @entity1188 ), 19 of 31 @entity1 with @entity1188 ( @entity1188 ), and 30 of 36 @entity1 with cardiogenic @entity1188 (CE). @entity7244 were significantly less frequent in @entity1188 than in @entity1188 and CE, and more frequent in CE than in @entity63 . @entity7244 were more prevalent in @entity1 with medium-to-large DWI-assessed lesions than in those with small lesions on DWI. @entity1 with medium-sized lesions following @entity1188 and CE had a high frequency of diffusion-perfusion mismatch. In 4 of the 5 @entity1 who underwent intravenous thrombolytic therapy, ASL hypoperfusion and diffusion-perfusion mismatch were improved and the occluded arteries were recanalized. CONCLUSIONS: ASL perfusion studies may provide useful clinical information allowing diffusion-perfusion mismatch detection and treatment selection in @entity64 @entity1 , depending on @entity64 subtype.

title: Distinctive Patterns of Three-Dimensional Arterial XXXX -Labeled Perfusion Magnetic Resonance Imaging in Subtypes of Acute Ischemic Stroke.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['acute ischemic stroke', 'AIS', 'stroke', 'different stroke subtypes', 'Stroke']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['transient ischemic attack', 'TIA']

entities_list: @entity7244 :: ('MESH:D020765', 'Disease') :: ['ASL abnormalities']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['LI', 'embolic infarction', 'atherothrombotic infarction', 'AT', 'lacunar infarction']

answer: @entity7959 :: (10927,Gene) :: ['Spin']


abstract: CONTEXT: @entity1184 ( @entity1184 ) and acne-like skin eruptions are frequent during the first months of life, yet the etiology and prevalence of these conditions in @entity1 are not clear. OBJECTIVE: The objective of the study was to evaluate the association of postnatal @entity3800 with @entity1184 and acne in @entity1 . DESIGN: This was a longitudinal, monthly follow-up from 1 wk (D7) to 6 months of age (M1-M6). @entity1 : @entity1 included 54 full-term (FT; 26 @entity1 ) and 48 preterm (PT; gestational age at birth 27.7-36.6 wk, 22 @entity1 ) @entity1 . MAIN OUTCOME MEASURES: The occurrence of @entity1184 (present/absent) and acne (5-10, 10-50, and >50 papules) was registered and compared with urinary levels of @entity2494 and its @entity597 and @entity251 measured by liquid chromatography-tandem mass spectrometry. RESULTS: @entity1184 was observed in 89% of FT and 96% of PT @entity1 (P = 0.28). Acne (more than five papules) was observed in 91% of FT @entity1 and in 75% of PT @entity1 (P = 0.06). Both @entity1184 and acne were associated with developmental rather than calendar age: @entity1184 was limited to postmenstrual age less than 46 wk and acne was not observed less than 37 wk of postmenstrual age. Urinary @entity342 levels showed severalfold differences in magnitude between sexes and between the FT and PT groups. After grouping according to sex and maturity, the occurrence of @entity1184 and the severity of acne were associated with higher urinary @entity2990 and @entity251 levels in each group. CONCLUSIONS: @entity1184 and acne are common during the first months of life and associated with endogenous, physiologically elevated levels of @entity3800 originating from the adrenals and gonads. These data suggest a novel role for postnatal @entity342 secretion in infancy.

title: Transient postnatal secretion of @entity342 hormones is associated with acne and XXXX in early infancy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'boys', 'PATIENTS', 'infants']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity2990 :: ('CHEBI:16814', 'Chemical') :: ['dehydroepiandrosterone sulphate']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['Sebaceous gland hypertrophy', 'SGH']

entities_list: @entity2494 :: ('MESH:D003687', 'Chemical') :: ['dehydroepiandrosterone']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity3800 :: ('MESH:D000728', 'Chemical') :: ['androgens']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulphate']

answer: @entity1184 :: (MESH:D006984,Disease) :: ['sebaceous gland hypertrophy']


abstract: @entity6071 ( @entity6071 ) are evolutionarily prevalent recognition molecules in the Animalia and Plantae kingdom, which play vital roles in immune defense and homeostasis maintenance. Recently, the expansion of @entity6071 has been reported in invertebrate genomes, but the characters and immune functions of these expanded @entity6071 were still not well known. In the present study, a new member of TLR family with five LRR domains was identified in @entity6796 (designated CgTLR6). It shared homology with @entity6071 from other organisms with the closest phylogenic relationship with molluscan @entity6071 . The recombinant protein of CgTLR6 (rCgTLR6) displayed direct bind activity to gram-negative bacteria @entity2551 and @entity20875 , gram-positive bacteria Staphylococci aureus and @entity7178 , and fungi @entity10056 , but not to fungi @entity10057 . It also exhibited affinity to lipopolysaccharide (LPS) and peptidoglycan (PGN), while no affinity to mannan ( @entity1 ). The mRNA of CgTLR6 was mainly detected in hemocytes and hepatopancreas, and was significantly induced (p  <  0.01) in hemocytes after the oyster was stimulated with LPS, PGN or bacteria @entity20875 . Immunofluorescence analysis indicated that CgTLR6 was mainly located at the membrane of hemocytes. The blockage of CgTLR6 by anti-rCgTLR6 antibody did not significantly inhibit the phagocytic rates of hemocytes toward recognized gram-negative bacteria @entity2551 and @entity20875 , and unrecognized fungi @entity10057 . These results collectively implied that CgTLR6 was a novel non-phagocytic receptor of @entity6796 to mediate humoral immune response by recognizing pathogen-associated molecular patterns on the invaders.

title: A new non-phagocytic TLR6 with broad recognition ligands from XXXX @entity6796 .

entities_list: @entity6071 :: ('MESH:C562709', 'Disease') :: ['Toll like receptors', 'TLRs']

entities_list: @entity10056 :: ('4922', 'Species') :: ['Pichia pastoris']

entities_list: @entity20875 :: ('29497', 'Species') :: ['V. splendidus', 'Vibrio splendidus']

entities_list: @entity2551 :: ('55601', 'Species') :: ['Vibrio anguillarum', 'V. anguillarum']

entities_list: @entity10057 :: ('4952', 'Species') :: ['Yarrowia lipolytica', 'Y. lipolytica']

entities_list: @entity7178 :: ('1270', 'Species') :: ['Micrococcus luteus']

entities_list: @entity6796 :: ('29159', 'Species') :: ['Crassostrea gigas', 'C. gigas']

answer: @entity6796 :: (29159,Species) :: ['Pacific oyster']


abstract: Ablation procedures for @entity955 are being performed with increasing frequency. One of the most serious complications is the development of @entity849 , which occurs in 1% to 3% of current series. The presentation of @entity849 varies widely. The majority of @entity1 are symptomatic although specific referral bias patterns can affect this. Symptoms may include @entity1353 or hemoptysis or may be consistent with @entity3617 . These symptoms are affected by the number of stenotic veins as well as the severity of the @entity850 . The more severe the @entity850 and the greater number of stenosed veins result in more symptoms. Because of the variability in symptoms, clinicians must have heightened sensitivity to the presence of the condition. Diagnostic tests of value include magnetic resonance angiography and computed tomography. Although echocardiography has been used, it does not usually provide adequate assessment. Progression of @entity850 is unpredictable and may be rapid. The specific anatomy of the @entity850 varies widely and affects management. Because of the presence of antral fusion of the origin of the left superior and left inferior pulmonary vein, a @entity850 involving 1 or the other can impinge and affect outcome. In this setting, bifurcation techniques familiar to interventional cardiology are very helpful. Controversy currently exists about the optimal treatment approach. The use of balloons and larger stents (approximately 10 mm) results in more optimal results than just balloon angioplasty alone; however, even with stent implantation, recurrent @entity256 may occur in 30% to 50% of @entity1 . Follow-up of these @entity1 typically involves computed tomography imaging to document @entity256 . If significant @entity256 is identified, it should be treated promptly because of the potential for progression to @entity432 .

title: @entity849 complicating ablation for XXXX : clinical spectrum and interventional considerations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']

entities_list: @entity849 :: ('MESH:D011666', 'Disease') :: ['pulmonary vein stenosis']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['total occlusion']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: AIM: Despite improvement in the operative technique and graft and suture material, femoral @entity439 (FAAs) represent a continuing problem for @entity1 undergoing lower extremity revascularization. The present retrospective study investigates the clinical presentation, the @entity281 as a cause of FAAs, the interval between the original operation and the development of FAAs. It also evaluates the mortality and amputation rate of @entity1 with FAAs. METHODS: We reviewed the records of 124 @entity1 (thrombendarterectomy in 9, femoro-femoral bypass in 3 and axillofemoral bypass in 1). RESULTS: There were 13 infected and 14 recurrent FAAs. The overall mean time elapsing between the initial operation and the development of FAAs was 56.9 months (range 1-219). This interval was 62 months for the noninfected FAAs, while it was only 8 months for the infected FAAs. The mean time interval in which a recurrence of FAAs occurred was 39 months. The most common type of repair was an interposition prosthetic graft from the proximal prosthesis to the profunda femoral artery (100 cases). In the postoperative period local complications occurred in 21 (15.4%) cases and systemic in 7 (5.1%). The postoperative mortality was 3.7%. The overall survival at 1 year was 91.3% (standard error: +/-2.5%) and at 2 years 85.4% (standard error: +/-3.3%). Kaplan-Meier analysis showed a cumulative limb salvage of 94.2%, 93.3 % and 89.2% after 6 months, 1 and 2 years, respectively. A significant relationship was demonstrated between amputation and the following parameters: infected FAAs (Log rank test: 26.1, P-value <0.001), @entity6 (Log-rank test: 12.9, P-value <0.01), peripheral @entity432 (Log-rank test: 3.1, P-value =0.08), and prior limb amputation (Log-rank test: 9.9, P-value <0.01). The mean time to amputation for the infected FAAs was 49.6 months (95% CI: 24.3-74.8), while for the noninfected it was 98.8 months (95% CI: 93.4-104.2). CONCLUSIONS: Complicated FAAs are still responsible for significant morbidity and mortality. Elective treatment produce the maximum benefit.

title: Femoral XXXX in the modern era: a reappraisal of a continuing challenge.

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['anastomotic aneurysms']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['arterial occlusive disease']

answer: @entity439 :: (MESH:D000783,Disease) :: ['anastomotic aneurysms']


abstract: Fourteen cases of neoplasms metastatic to the ovaries in @entity1 10 weeks to 15 years of age are reported. Eight @entity5 were @entity521 , 7 primary in the adrenal gland, and 1 primary in the posterior mediastinum. Three @entity5 were @entity980 primary in the ethmoid sinus, right occipital region, and left thigh, respectively. The final three @entity5 were a @entity2828 , a @entity5606 , and a @entity5 primary in the fibula, kidney, and lung, respectively. The ovarian involvement was an autopsy finding in nine of the @entity1 . Three of the remaining five @entity1 presented clinically with manifestations suggesting a primary @entity43 , and the final two @entity1 , who had known extraovarian @entity5 , had symptomatic ovarian masses discovered during life. In one case of @entity521 and the case of @entity5606 , the ovarian metastases were initially misinterpreted pathologically as primary @entity43 ; the primary @entity703 was not discovered until autopsy in the latter case. The @entity43 were bilateral in 8 of the 14 cases. @entity2670 was present in 10 cases. Our experience and that in the literature indicates that the @entity5 that spreads to the ovary most frequently is the @entity521 and that @entity980 is the most common @entity242 of childhood that spreads to the ovary. The clinical features and the frequent bilaterality of ovarian @entity3 are helpful diagnostic features in many cases, but when the @entity43 is the presenting manifestation of the disease, is unilateral, or both, differentiation from various primary @entity43 may be difficult.

title: Metastatic XXXX in @entity1 : a report of 14 cases and review of the literature.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity2828 :: ('MESH:D012512', 'Disease') :: ["Ewing's sarcoma"]

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancers', 'ovarian tumors', 'ovarian tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumors', 'childhood tumor', 'carcinoid tumor', 'tumors']

entities_list: @entity5606 :: ('MESH:D018335', 'Disease') :: ['rhabdoid tumor']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastomas', 'neuroblastoma']

entities_list: @entity2670 :: ('MESH:D010049', 'Disease') :: ['Ovarian enlargement']

entities_list: @entity980 :: ('MESH:D012208', 'Disease') :: ['rhabdomyosarcoma', 'rhabdomyosarcomas']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumor']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian tumors']


abstract: @entity10433 ( @entity10433 ) is persistently activated in @entity5 cells and contributes to malignant progression in various types of @entity5 . The Janus-activated kinase (JAK) family phosphorylates @entity10433 in response to stimulation by cytokines or growth factors. The @entity40263 - @entity10433 signaling pathway plays an important role in cell proliferation and apoptosis. @entity40273 (NC) is a @entity25091 that has been reported as an antitumor agent due to its its inhibitory effects on topoisomerase I. Using a @entity19 xenograft model of @entity157 ( @entity157 ), this study aimed to evaluate the effects of NC on @entity5 growth in vivo and to elucidate the underlying mechanisms. The analysis of the effects of NC on apoptosis in @entity96 xenografts in @entity19 was carried out by terminal deoxynucleotidyl transferase-mediated @entity1977 nick end-labeling (TUNEL) assay; the expression of @entity1379 , @entity1380 , cyclin-dependent kinase ( @entity11953 , @entity1896 , @entity5207 and @entity4698 ( @entity4698 ) was analyzed by immunohistochemistry; and the protein expression of @entity40263 and @entity10433 was examined by western blot analysis. Our results revealed that treatment with NC decreased the @entity5 volume and @entity5 weight, suggesting that NC inhibits @entity157 cell growth in vivo. In addition, NC blocked the activation of @entity40263 - @entity10433 in the @entity5 tissues, which in turn resulted in the induction of @entity5 cell apoptosis and the inhibition of proliferation. Consequently, treatment with NC downregulated the expression of @entity1896 , @entity11953 and @entity1379 and increased the level of @entity5207 and @entity1380 . Our data provide a molecular basis for the antitumor activity of NC.

title: XXXX inhibits @entity157 cell growth in vivo through the suppression of the @entity40263 / @entity10433 signaling pathway.

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['HCC tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity10433 :: ('20848(Tax:10090)', 'Gene') :: ['STAT3', 'Signal transducer and activator of transcription 3']

entities_list: @entity4698 :: ('18538(Tax:10090)', 'Gene') :: ['PCNA', 'proliferating cell nuclear antigen']

entities_list: @entity40273 :: ('MESH:C013615', 'Chemical') :: ['Nitidine chloride']

entities_list: @entity25091 :: ('CHEBI:38517', 'Chemical') :: ['benzophenanthridine alkaloid']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma', 'HCC']

answer: @entity40273 :: (MESH:C013615,Chemical) :: ['Nitidine chloride']


abstract: BACKGROUND: Metastatic @entity356 remains a significant problem as the majority of Western @entity1 are diagnosed with disseminated disease and no routine therapeutic regimen is accepted in such cases. METHODS: A cohort of 3141 @entity1 with @entity356 operated between 1990 and 2005 was evaluated using a multicenter data set held by the Polish @entity356 Study Group to determine potential risks and benefits of non-curative gastrectomy for @entity3 . Additionally, parameters of Quality of Life (QoL) were evaluated prospectively in 140 @entity1 undergoing gastrectomy using the QLQ-C30 questionnaire. RESULTS: Gastrectomy was carried out in 2258 @entity1 . Distant organ metastases were diagnosed in 951 @entity1 , 415 of which underwent non-curative gastrectomy. The overall mortality rates were significantly higher in @entity1 undergoing non-resectional surgery (10%) than either curative (3%, P < 0.001) or non-curative (4%, P = 0.002) gastrectomy. The overall median survival in @entity1 with @entity3 was significantly higher for non-curative gastrectomy (10.6 months, 95% confidence interval (CI) 9.3-11.9) than for non-resective operations (4.4 months, 95% CI 4.0 to 4.8, P < 0.001). The hazard ratio of @entity204 in @entity1 subject to non-resectional surgery compared to those treated by gastrectomy was 2.923 (95% CI 2.473 to 3.454, P < 0.001). A gradual impairment in QoL parameters was found over 12 months after non-curative resections but changes did not reach statistical significance and individual parameters were similar to gastrectomy without distant metastases. CONCLUSION: Non-curative gastrectomy for metastatic @entity356 is associated with significantly better survival compared to non-resective surgery and does not impair quality of life.

title: Non-curative gastrectomy for metastatic XXXX : rationale and long-term outcome in multicenter settings.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'Gastric Cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']